Small molecules drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form and, cost-effectiveness. The small molecule drug discovery market is expected to witness huge growth due to increasing approval of small molecule drugs, growing demand for R&D from contract organizations, and rising adoption of small molecules in chronic disease treatments. However, high drug development cost is expected to restrain the growth of the market during the forecast period.
The small molecule drug discovery market was valued at US$ 24,976.14 million in 2019 and is projected to reach US$ 50,823.06 Mn by 2027; it is expected to grow at a CAGR of 9.5% from 2020 to 2027.
Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPRE00004774/
- Johnson and Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
- Allergan Plc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- MERCK KGaA
- GlaxoSmithKline plc.
- Gilead Sciences, Inc.
Based on therapeutic area, the small molecule drug discovery market is segmented into oncology, central nervous system, cardiovascular, respiratory, orthopedics, immunology, rare diseases, and other therapeutic areas. The oncology segment held a largest share of the market in 2019 owing to the increasing small molecule drug approvals and growing pipeline for the cancer therapeutics. Moreover, increasing investment in oncology is further driving the growth of the segment. For instance, In December 2019, Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, completed US$ 85 million Series C financing. However, the rare diseases segment is expected to register a higher CAGR in the market during the forecast period.
As per the Centres for Disease Control (CDC), 6 in 10 adults suffer from a chronic condition, such as heart disease, diabetes, cancer, kidney disease, lung disease, or stroke in the US, costing US$ 3.5 trillion to the economy in the US annually for the treatment of these chronic diseases. Chronic diseases are the most significant cause of deaths worldwide, and the number is growing every year. For instance, as per the CDC, more than 1.6 million people are diagnosed with cancer every year in the US.
Small-molecule medicines are expected to provide effective treatment options for chronic diseases owing to their size and ability to cross cell barriers. They can also be designed to cross the blood-brain barrier to target neurological illnesses. Small molecules are expected to play a critical role in reducing the burden of chronic disease. In the coming years, small molecules are expected to help with the formulation of more efficient and effective treatments for chronic conditions.
Small Molecule Drug Discovery Market – By Therapeutic Area
- Central Nervous System
- Rare Diseases
- Other Therapeutic Areas
Small Molecule Drug Discovery Market – By Process/Phase
- Target Discovery
- Target Validation
- Lead Generation and Refinement
- Preclinical Development
Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPRE00004774/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.
Email: [email protected]